期刊文献+

TUBB3在体外化疗药物敏感试验肝细胞癌标本中的表达及意义 被引量:3

下载PDF
导出
摘要 目的探讨体外药敏试验在肝细胞癌(HCC)个体化化疗的应用以及TUBB3在HCC中的表达及意义。方法应用组织培养药敏试验检测100例手术切除HCC组织的化疗药物敏感性,并通过免疫组化法检测100例HCC组织、配对癌旁组织和10例正常肝组织中TUBB3的表达。结果 HCC组织对化疗药物敏感率由高到低为紫杉醇、伊立替康、丝裂霉素、亚砷酸、卡铂、氟脲苷、表柔比星、奥沙利铂和吉西他滨;TUBB3在HCC组织中的表达水平明显高于癌旁组织和正常肝组织,在肿瘤直径>6 cm(P=0.025)、多发肿瘤(P=0.042)和TNMⅢ期(P=0.012)中表达较高,是术后总生存的危险因素(P=0.032);TUBB3表达与紫杉醇耐药(r=0.321,P=0.001)和丝裂霉素耐药(r=0.215,P=0.033)呈正相关。结论组织培养药敏试验法可作为HCC患者个体化化疗药物筛选的手段,TUBB3可作为化疗药物疗效评价和肿瘤侵袭性的生物标记。
出处 《广东医学》 CAS CSCD 北大核心 2012年第18期2750-2753,共4页 Guangdong Medical Journal
基金 广州市科学技术经费项目(编号:2012J4300078)
  • 相关文献

参考文献18

  • 1JEMAL A, BRAY F, CENTER M M, et al. Global cancer statis- tics[J]. CACancerJClin, 2011, 61(2) : 69 -90.
  • 2FROMOWITZ F B, VIOLA M V, CHAO S, et al. ras p21 expres- sion in the progression of breast cancer [ J ]. Hum Pathol, 1987, 18(12) : 1268 -1275.
  • 3YOON Y S, KIM C W, ROH S A, et al. Applicability of histocul- ture drug response assays in colorectal cancer chemotherapy [ J ]. Anticancer Res, 2012,32(8) :3581 -3586.
  • 4FUJITA Y, HIRAMATSU M, KAWAI W, et al. Histoculture drug response assay predicts the postoperative prognosis of patients with esophageal cancer [ J ]. Oncol Rep, 2009,21 (2) :499 - 505.
  • 5陈涛,楮忠华,刘建平,王捷,赵海燕,区庆嘉.体外化疗药物敏感实验对指导原发性肝癌个体化疗的临床意义[J].癌症,2005,24(8):1018-1022. 被引量:24
  • 6CHUU J J, LIU J M, TSOU M H, et al. Effects of paclitaxel and doxombicin in histocuhures of hepatocelular carcinomas[ J]. J Bi-omed Sei, 2007, 14(2) : 233 -244.
  • 7MATSUOKA H, YANO K, SAITO T, et al. Cytotoxicity of pacli- taxel in comparison with other anticancer agents against neoplastic ceils obtained from clinical gastrointestinal carcinoma tissue [ J ]. Anticancer Res, 1995, 15(5B): 2001-2006.
  • 8ZHOU Q, CHING A K, LEUNG W K, et al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin - bound paclitaxel in hepatocellular carcinoma[J]. Int J Oncol, 2011, 38 (3) : 721 -731.
  • 9CHAO Y, CHAN W K, BIRKHOFER M J, et al, Phase II and pharmacokinetic study of paclitaxel therapy for unreseetable hepa- tocellular carcinoma patients [ J ]. Br J Cancer, 1998, 78 ( 1 ) : 34 - 39.
  • 10LLOVET J M, BRUIX J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization im- proves survival[ J ]. Hepatology, 2003, 37 (2) : 429 - 442.

二级参考文献12

  • 1Kurbacher CM, Grecu OM, Stier U, et al. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials [J].Recent Results Cancer Res, 2003,161:221-230.
  • 2Sevin BU, Peng Z, Perras J, et al. Application of an ATP bioluminescence assay in human tumor chemosensitivity testing [J]. Gynecol Oncol, 1988,31(1): 191-204.
  • 3Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma [J]. Cancer Res,1995,55 ( 22 ): 5276-5282.
  • 4Kurbacher CM, Mallmann P, Kurbacher JA, et al. In vitro activity of titanocenedichloride versus cisplatin and doxombicin in primary and recurrent epithelial ovarian cancer [J].Anticancer Res, 1994,14(5A): 1961-1965.
  • 5Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays [J]. J Immunol Methods, 1983,55 (1-2): 65-67.
  • 6Yamaue H, Tanimura H, Tsunoda T, et al. Chemosensitivity testing with highly purified fresh human tumour cells with the MTT colorimetric assay [J]. Eur J Cancer, 1991,27(10):1258-1262.
  • 7Weisenthal LM, Lippman ME. Clonogenic and nonclonogenic in vitro chemosensitivity assays [J]. Cancer Treat Rep, 1985,69(6): 615-632.
  • 8Cree IA, Kurbacher CM, Untch M, et al. Corre'ation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity [J]. Anticancer Drugs, 1996,7(6) :630-635.
  • 9Whitehouse PA, Mercer S J, Knight LA, et al. Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C [J]. Br J Cancer,2003,89 (12): 2299-2304.
  • 10Mercer SJ, Somers SS, Knight LA, et al. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma [J].Anticancer Drugs, 2003,14(6) :397-403.

共引文献23

同被引文献13

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部